{"id": "1EPjsEMAAAAJ", "citedby": 19539, "citedby5y": 8659, "hindex": 66, "hindex5y": 51, "i10index": 133, "i10index5y": 112, "coauthors": [], "name": "Rachel Schiff", "affiliation": "Baylor College of Medicine", "interests": [], "cites_per_year": {"1999": 54, "2000": 96, "2001": 106, "2002": 182, "2003": 222, "2004": 312, "2005": 565, "2006": 700, "2007": 701, "2008": 887, "2009": 843, "2010": 895, "2011": 1076, "2012": 1222, "2013": 1388, "2014": 1400, "2015": 1613, "2016": 1627, "2017": 1499, "2018": 1587, "2019": 1626, "2020": 692}, "publications": [{"bib": {"title": "Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2\u2013positive breast cancer", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:u5HHmVD_uO8C", "citedby": "1276"}, {"bib": {"title": "Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:u-x6o8ySG0sC", "citedby": "909"}, {"bib": {"title": "Mechanisms of endocrine resistance in breast cancer", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:UeHWp8X0CEIC", "citedby": "856"}, {"bib": {"title": "Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes", "year": "1998"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:d1gkVwhDpl0C", "citedby": "781"}, {"bib": {"title": "Estrogen receptor\u2013positive, progesterone receptor\u2013negative breast cancer: association with growth factor receptor expression and tamoxifen resistance", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:9yKSN-GCB0IC", "citedby": "511"}, {"bib": {"title": "Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:IjCSPb-OGe4C", "citedby": "503"}, {"bib": {"title": "Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:qjMakFHDy7sC", "citedby": "498"}, {"bib": {"title": "Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:2osOgNQ5qMEC", "citedby": "489"}, {"bib": {"title": "Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Tyk-4Ss8FVUC", "citedby": "473"}, {"bib": {"title": "Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Y0pCki6q_DkC", "citedby": "461"}, {"bib": {"title": "Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:zYLM7Y9cAGgC", "citedby": "452"}, {"bib": {"title": "The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Se3iqnhoufwC", "citedby": "419"}, {"bib": {"title": "Estrogen-receptor biology: continuing progress and therapeutic implications", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:W7OEmFMy1HYC", "citedby": "408"}, {"bib": {"title": "Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:YsMSGLbcyi4C", "citedby": "402"}, {"bib": {"title": "HER2: biology, detection, and clinical implications", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hqOjcs7Dif8C", "citedby": "387"}, {"bib": {"title": "A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:UebtZRa9Y70C", "citedby": "310"}, {"bib": {"title": "A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:9ZlFYXVOiuMC", "citedby": "303"}, {"bib": {"title": "Au nanomatryoshkas as efficient near-infrared photothermal transducers for cancer treatment: benchmarking against nanoshells", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:IWHjjKOFINEC", "citedby": "272"}, {"bib": {"title": "Neoadjuvant trastuzumab induces apoptosis in primary breast cancers", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:eQOLeE2rZwMC", "citedby": "269"}, {"bib": {"title": "ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:70eg2SAEIzsC", "citedby": "261"}, {"bib": {"title": "MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:qUcmZB5y_30C", "citedby": "260"}, {"bib": {"title": "Estrogen Dendrimer Conjugates that Preferentially Activate Extranuclear, Nongenomic Versus Genomic Pathways of Estrogen Action", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_FxGoFyzp5QC", "citedby": "260"}, {"bib": {"title": "Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo", "year": "2000"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:LkGwnXOMwfcC", "citedby": "248"}, {"bib": {"title": "Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:MXK_kJrjxJIC", "citedby": "240"}, {"bib": {"title": "Statistical analysis of array expression data as applied to the problem of tamoxifen resistance", "year": "1999"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WF5omc3nYNoC", "citedby": "238"}, {"bib": {"title": "Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2 \u2026", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:3fE2CSJIrl8C", "citedby": "234"}, {"bib": {"title": "Expression of wild-type estrogen receptor \u03b2 and variant isoforms in human breast cancer", "year": "1999"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ufrVoPGSRksC", "citedby": "233"}, {"bib": {"title": "Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:kNdYIx-mwKoC", "citedby": "218"}, {"bib": {"title": "Estrogen receptor \u03b2 protein in human breast cancer: correlation with clinical tumor parameters", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:roLk4NBRz8UC", "citedby": "218"}, {"bib": {"title": "Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 \u2026", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4DMP91E08xMC", "citedby": "212"}, {"bib": {"title": "Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor 2 overexpression in breast cancer", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:5nxA0vEk-isC", "citedby": "206"}, {"bib": {"title": "Estrogen receptor: current understanding of its activation and modulation", "year": "2001"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:0EnyYjriUFMC", "citedby": "206"}, {"bib": {"title": "Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Wp0gIr-vW9MC", "citedby": "202"}, {"bib": {"title": "Treatment of human epidermal growth factor receptor 2\u2013overexpressing breast cancer xenografts with multiagent HER-targeted therapy", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:8k81kl-MbHgC", "citedby": "195"}, {"bib": {"title": "Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Zph67rFs4hoC", "citedby": "186"}, {"bib": {"title": "Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor\u2013positive, HER-2/neu-positive breast cancer", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:KlAtU1dfN6UC", "citedby": "170"}, {"bib": {"title": "Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ULOm3_A8WrAC", "citedby": "169"}, {"bib": {"title": "Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:mVmsd5A6BfQC", "citedby": "168"}, {"bib": {"title": "Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:YOwf2qJgpHMC", "citedby": "165"}, {"bib": {"title": "Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor\u2013positive metastatic breast cancer: a randomized phase ii study", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4TOpqqG69KYC", "citedby": "161"}, {"bib": {"title": "Tracking of multimodal therapeutic nanocomplexes targeting breast cancer in vivo", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:qxL8FJ1GzNcC", "citedby": "157"}, {"bib": {"title": "\u03b21 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hC7cP41nSMkC", "citedby": "148"}, {"bib": {"title": "Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:M3ejUd6NZC8C", "citedby": "148"}, {"bib": {"title": "Metastasis dormancy in estrogen receptor\u2013positive breast cancer", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4JMBOYKVnBMC", "citedby": "142"}, {"bib": {"title": "Targeting HER2 for the treatment of breast cancer", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hMod-77fHWUC", "citedby": "139"}, {"bib": {"title": "Inhibition of AP-1 transcription factor causes blockade of multiple signal transduction pathways and inhibits breast cancer growth", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_kc_bZDykSQC", "citedby": "136"}, {"bib": {"title": "An epigenomic approach to therapy for tamoxifen-resistant breast cancer", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:iH-uZ7U-co4C", "citedby": "135"}, {"bib": {"title": "Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:L8Ckcad2t8MC", "citedby": "135"}, {"bib": {"title": "Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:aqlVkmm33-oC", "citedby": "128"}, {"bib": {"title": "Estrogen-mediated down-regulation of E-cadherin in breast cancer cells", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:QIV2ME_5wuYC", "citedby": "126"}, {"bib": {"title": "The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:7PzlFSSx8tAC", "citedby": "110"}, {"bib": {"title": "Cancer cells resistant to therapy promote cell surface relocalization of GRP78 which complexes with PI3K and enhances PI (3, 4, 5) P3 production", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:j3f4tGmQtD8C", "citedby": "103"}, {"bib": {"title": "Immunoconjugated gold nanoshell-mediated photothermal ablation of trastuzumab-resistant breast cancer cells", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:mB3voiENLucC", "citedby": "103"}, {"bib": {"title": "Upregulation of PKC-\u03b4 contributes to antiestrogen resistance in mammary tumor cells", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:dhFuZR0502QC", "citedby": "99"}, {"bib": {"title": "Proteomic analysis of tumor necrosis factor-\u03b1 resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:-f6ydRqryjwC", "citedby": "98"}, {"bib": {"title": "Recurrent ESR1\u2013CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:RGFaLdJalmkC", "citedby": "95"}, {"bib": {"title": "Molecular profiles of progesterone receptor loss in human breast tumors", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hFOr9nPyWt4C", "citedby": "95"}, {"bib": {"title": "Sphingosine kinase 1 induces tolerance to human epidermal growth factor receptor 2 and prevents formation of a migratory phenotype in response to sphingosine 1-phosphate in \u2026", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:TQgYirikUcIC", "citedby": "94"}, {"bib": {"title": "Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ZeXyd9-uunAC", "citedby": "89"}, {"bib": {"title": "Hydrogen sulfide improves wound healing via restoration of endothelial progenitor cell functions and activation of angiopoietin-1 in type 2 diabetes", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:k8Z6L05lTy4C", "citedby": "82"}, {"bib": {"title": "Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-\u03b1 function and its implication for endocrine therapy resistance in breast cancer", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:HDshCWvjkbEC", "citedby": "78"}, {"bib": {"title": "Biological mechanisms and clinical implications of endocrine resistance in breast cancer", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_Qo2XoVZTnwC", "citedby": "77"}, {"bib": {"title": "Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:R3hNpaxXUhUC", "citedby": "74"}, {"bib": {"title": "Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:bEWYMUwI8FkC", "citedby": "72"}, {"bib": {"title": "Sub-100 nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:NaGl4SEjCO4C", "citedby": "71"}, {"bib": {"title": "Bidirectional crosstalk between the estrogen receptor and human epidermal growth factor receptor 2 signaling pathways in breast cancer: molecular basis and clinical implications", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:RYcK_YlVTxYC", "citedby": "69"}, {"bib": {"title": "Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:RHpTSmoSYBkC", "citedby": "65"}, {"bib": {"title": "Perspective on circulating tumor cell clusters: why it takes a village to metastasize", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_5tno0g5mFcC", "citedby": "61"}, {"bib": {"title": "The dynamics of estrogen receptor status in breast cancer: re-shaping the paradigm", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:isC4tDSrTZIC", "citedby": "59"}, {"bib": {"title": "FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:lmc2jWPfTJgC", "citedby": "58"}, {"bib": {"title": "The changing role of ER in endocrine resistance", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:uWQEDVKXjbEC", "citedby": "57"}, {"bib": {"title": "Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ns9cj8rnVeAC", "citedby": "56"}, {"bib": {"title": "Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or \u2026", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:vV6vV6tmYwMC", "citedby": "53"}, {"bib": {"title": "Compartmentalized Ras proteins transform NIH 3T3 cells with different efficiencies", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:JV2RwH3_ST0C", "citedby": "53"}, {"bib": {"title": "Cytoplasmic estrogen receptor in breast cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:maZDTaKrznsC", "citedby": "52"}, {"bib": {"title": "Embryonic transcription factor SOX9 drives breast cancer endocrine resistance", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:bz8QjSJIRt4C", "citedby": "50"}, {"bib": {"title": "Spatial proximity to fibroblasts impacts molecular features and therapeutic sensitivity of breast cancer cells influencing clinical outcomes", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:b1wdh0AR-JQC", "citedby": "49"}, {"bib": {"title": "Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_xSYboBqXhAC", "citedby": "49"}, {"bib": {"title": "Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:pyW8ca7W8N0C", "citedby": "47"}, {"bib": {"title": "TBCRC 006: A multicenter phase II study of neoadjuvant lapatinib and trastuzumab in patients with HER2-overexpressing breast cancer.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:e5wmG9Sq2KIC", "citedby": "47"}, {"bib": {"title": "Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:r0BpntZqJG4C", "citedby": "47"}, {"bib": {"title": "The evolving role of the estrogen receptor mutations in endocrine therapy-resistant breast cancer", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:5qfkUJPXOUwC", "citedby": "46"}, {"bib": {"title": "PDEF promotes luminal differentiation and acts as a survival factor for ER-positive breast cancer cells", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:g5m5HwL7SMYC", "citedby": "45"}, {"bib": {"title": "Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ZHo1McVdvXMC", "citedby": "44"}, {"bib": {"title": "Transcriptional activation of mouse retrotransposons in vivo: specific expression in steroidogenic cells in response to trophic hormones.", "year": "1991"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:TFP_iSt0sucC", "citedby": "44"}, {"bib": {"title": "Pathway-centric integrative analysis identifies RRM2 as a prognostic marker in breast cancer associated with poor survival and tamoxifen resistance", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:rO6llkc54NcC", "citedby": "43"}, {"bib": {"title": "Systemic mirnas as potential biomarkers for malignancy", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:M3NEmzRMIkIC", "citedby": "42"}, {"bib": {"title": "Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:k_IJM867U9cC", "citedby": "40"}, {"bib": {"title": "SGK3 is associated with estrogen receptor expression in breast cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:3s1wT3WcHBgC", "citedby": "39"}, {"bib": {"title": "HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Ri6SYOTghG4C", "citedby": "38"}, {"bib": {"title": "Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:a0OBvERweLwC", "citedby": "38"}, {"bib": {"title": "Aromatase inhibitors: future directions", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:O3NaXMp0MMsC", "citedby": "34"}, {"bib": {"title": "Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:M05iB0D1s5AC", "citedby": "32"}, {"bib": {"title": "Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs)", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:BqipwSGYUEgC", "citedby": "32"}, {"bib": {"title": "New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:YFjsv_pBGBYC", "citedby": "30"}, {"bib": {"title": "Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2\u2013ER\u03b1\u2013GREB1 Transcriptional Axis", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:sNmaIFBj_lkC", "citedby": "29"}, {"bib": {"title": "Abstract S6-02: TBCRC023: A randomized multicenter phase II neoadjuvant trial of lapatinib plus trastuzumab, with endcorine therapy and without chemotherapy, for 12 vs. 24 \u2026", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:fPk4N6BV_jEC", "citedby": "29"}, {"bib": {"title": "A noncompetitive small molecule inhibitor of estrogen-regulated gene expression and breast cancer cell growth that enhances proteasome-dependent degradation of estrogen receptor \u03b1", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:GnPB-g6toBAC", "citedby": "29"}, {"bib": {"title": "De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:0izLItjtcgwC", "citedby": "27"}, {"bib": {"title": "Expression and cellular localization of uterine side-chain cleavage cytochrome P450 messenger ribonucleic acid during early pregnancy in mice", "year": "1993"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:blknAaTinKkC", "citedby": "27"}, {"bib": {"title": "Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing \u2026", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:XvxMoLDsR5gC", "citedby": "26"}, {"bib": {"title": "Targeting the epidermal growth factor receptor pathway improves the anti-tumor effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer.", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:NMxIlDl6LWMC", "citedby": "26"}, {"bib": {"title": "Blockade of AP-1 potentiates endocrine therapy and overcomes resistance", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:dTyEYWd-f8wC", "citedby": "24"}, {"bib": {"title": "Dual roles for coactivator activator and its counterbalancing isoform coactivator modulator in human kidney cell tumorigenesis", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:HoB7MX3m0LUC", "citedby": "24"}, {"bib": {"title": "Local regulation within the female reproductive system and upon embryonic implantation: identification of cells expressing proenkephalin A", "year": "1990"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:lSLTfruPkqcC", "citedby": "23"}, {"bib": {"title": "Somatic expression of PyMT or activated ErbB2 induces estrogen-independent mammary tumorigenesis", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:2P1L_qKh6hAC", "citedby": "22"}, {"bib": {"title": "Allosteric binding site in a Cys-loop receptor ligand-binding domain unveiled in the crystal structure of ELIC in complex with chlorpromazine", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4fGpz3EwCPoC", "citedby": "21"}, {"bib": {"title": "Comprehensive functional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:MLfJN-KU85MC", "citedby": "21"}, {"bib": {"title": "Int6 regulates both proteasomal degradation and translation initiation and is critical for proper formation of acini by human mammary epithelium", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:pqnbT2bcN3wC", "citedby": "21"}, {"bib": {"title": "Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore \u2026", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ruyezt5ZtCIC", "citedby": "21"}, {"bib": {"title": "The importance of the estrogen receptor in breast cancer", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:J_g5lzvAfSwC", "citedby": "21"}, {"bib": {"title": "Photo activation of HPPH encapsulated in \u201cPocket\u201d liposomes triggers multiple drug release and tumor cell killing in mouse breast cancer xenografts", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:KxtntwgDAa4C", "citedby": "20"}, {"bib": {"title": "Amplification and over\u2010expression of MAP3K3 gene in human breast cancer promotes formation and survival of breast cancer cells", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:xtRiw3GOFMkC", "citedby": "20"}, {"bib": {"title": "Identification of MYST3 as a novel epigenetic activator of ER\u03b1 frequently amplified in breast cancer", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:-FonjvnnhkoC", "citedby": "19"}, {"bib": {"title": "PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a neoadjuvant trial of \u2026", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:rHJHxKgnXwkC", "citedby": "19"}, {"bib": {"title": "Estrogen receptor positive (ER+), progesterone receptor negative (PgR\u2212) breast cancer: new insights into molecular mechanisms and clinical implications", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:D03iK_w7-QYC", "citedby": "19"}, {"bib": {"title": "Molecular changes in tamoxifen-relapsed breast cancer: relationship between ER, HER2 and P38-MAP-kinase.", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ldfaerwXgEUC", "citedby": "17"}, {"bib": {"title": "The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WbkHhVStYXYC", "citedby": "16"}, {"bib": {"title": "Dominant-negative nuclear receptor corepressor relieves transcriptional inhibition of retinoic acid receptor but does not alter the agonist/antagonist activities of the \u2026", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:35N4QoGY0k4C", "citedby": "16"}, {"bib": {"title": "HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:wMgC3FpKEyYC", "citedby": "15"}, {"bib": {"title": "Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:cWzG1nlazyYC", "citedby": "15"}, {"bib": {"title": "Resistance to anti-HER2 therapies in breast cancer", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:08ZZubdj9fEC", "citedby": "15"}, {"bib": {"title": "More on FOX News: FOXA1 on the horizon of estrogen receptor function and endocrine response", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4OULZ7Gr8RgC", "citedby": "14"}, {"bib": {"title": "Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:P7Ujq4OLJYoC", "citedby": "13"}, {"bib": {"title": "Exploratory subset analysis according to prior endocrine treatment of two randomized phase II trials comparing gefitinib (G) with placebo (P) in combination with tamoxifen (T \u2026", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:zA6iFVUQeVQC", "citedby": "13"}, {"bib": {"title": "AIB1 as a prognostic marker and predictor of resistance to endocrine therapy", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:EUQCXRtRnyEC", "citedby": "13"}, {"bib": {"title": "Inhibiting the EGFR/HER2 pathway with gefitinib and/or trastuzumab restores tamoxifen sensitivity in HER2-overexpressing tumors", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:u_35RYKgDlwC", "citedby": "13"}, {"bib": {"title": "A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:jL-93Qbq4QoC", "citedby": "12"}, {"bib": {"title": "HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive \u2026", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:bKqednn6t2AC", "citedby": "12"}, {"bib": {"title": "Amplification of TLK2 Induces Genomic Instability via Impairing the G2\u2013M Checkpoint", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Y5dfb0dijaUC", "citedby": "12"}, {"bib": {"title": "The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:8xutWZnSdmoC", "citedby": "10"}, {"bib": {"title": "New insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:dfsIfKJdRG4C", "citedby": "10"}, {"bib": {"title": "Proceedings of the third international conference on recent advances and future directions in endocrine manipulation of breast cancer: Conference summary statement", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:cFHS6HbyZ2cC", "citedby": "10"}, {"bib": {"title": "Akt-dependent phosphorylation on AIB1 serine 967 contributes to breast cancer tamoxifen resistance.", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:f2IySw72cVMC", "citedby": "9"}, {"bib": {"title": "Int6 reduction activates stromal fibroblasts to enhance transforming activity in breast epithelial cells", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Tiz5es2fbqcC", "citedby": "8"}, {"bib": {"title": "Basal protein expression is associated with worse outcome and trastuzamab resistance in HER2+ invasive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:XiSMed-E-HIC", "citedby": "8"}, {"bib": {"title": "Onset of endocrine resistance in breast cancer is associated with increased active p38 MAPK.", "year": "2001"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:yD5IFk8b50cC", "citedby": "8"}, {"bib": {"title": "FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:yxmsSjX2EkcC", "citedby": "7"}, {"bib": {"title": "Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval \u2026", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4xDN1ZYqzskC", "citedby": "7"}, {"bib": {"title": "Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:QD3KBmkZPeQC", "citedby": "7"}, {"bib": {"title": "GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:mNrWkgRL2YcC", "citedby": "7"}, {"bib": {"title": "Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4hFrxpcac9AC", "citedby": "7"}, {"bib": {"title": "A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:7H_MAutzIkAC", "citedby": "6"}, {"bib": {"title": "AhR ligand aminoflavone suppresses \u03b16\u2010integrin\u2013Src\u2013Akt signaling to attenuate tamoxifen resistance in breast cancer cells", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:HeT0ZceujKMC", "citedby": "6"}, {"bib": {"title": "Gene expression profiles of ER+/PR\u2212 breast cancer are associated with genomic instability and Akt/mTOR signaling, and predict poor patient outcome better than clinically \u2026", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:bFI3QPDXJZMC", "citedby": "6"}, {"bib": {"title": "P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:K3LRdlH-MEoC", "citedby": "6"}, {"bib": {"title": "Expression of Estrogen Receptor \u03b2 Protein in Human Breast Cancer: Correlation with Clinical Tumor Parameters.", "year": "2000"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WZBGuue-350C", "citedby": "6"}, {"bib": {"title": "Reply [to \u201cComments on Paper by Richard Lee,\u2018The Hydrologic Importance of Transpiration Control by Stomata\u2019\u201d]", "year": "1968"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:9c2xU6iGI7YC", "citedby": "6"}, {"bib": {"title": "Towards personalized treatment for early stage HER2-positive breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hsZV8lGYWTMC", "citedby": "5"}, {"bib": {"title": "P38 MAPK pathway predicts endocrine-resistant growth of human breast cancer and provides a novel diagnostic and treatment target", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:l7t_Zn2s7bgC", "citedby": "5"}, {"bib": {"title": "Potent inhibition of EGFR (ErbB1)/HER2 (ErbB2) pathway plus estrogen deprivation is a superior therapeutic combination in ER positive HER2-neu over-expressing breast tumor \u2026", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:NhqRSupF_l8C", "citedby": "5"}, {"bib": {"title": "Inhibiting the growth factor receptor (GFR) pathway preserves and enhances the expression of the estrogen receptor (ER) in HER-2/neu (HER2) over-expressing human breast tumors \u2026", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:OU6Ihb5iCvQC", "citedby": "5"}, {"bib": {"title": "Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR\u2212 phenotype accompanied by EGFR/HER2 activation", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:b0M2c_1WBrUC", "citedby": "5"}, {"bib": {"title": "TBCRC023: a randomized phase II neoadjuvant trial of lapatinib plus trastuzumab without chemotherapy for 12 versus 24 weeks in patients with HER2-positive breast cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:owLR8QvbtFgC", "citedby": "4"}, {"bib": {"title": "Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:kVjdVfd2voEC", "citedby": "4"}, {"bib": {"title": "The FBXW2\u2013MSX2\u2013SOX2 axis regulates stem cell property and drug resistance of cancer cells", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:FiytvqdAVhgC", "citedby": "4"}, {"bib": {"title": "Trastuzumab-resistant HER2+ breast cancer cells retain sensitivity to poly (ADP-Ribose) polymerase (PARP) inhibition", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:KUbvn5osdkgC", "citedby": "4"}, {"bib": {"title": "PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:umqufdRvDiIC", "citedby": "4"}, {"bib": {"title": "Development of acneiform rash does not predict response to lapatinib treatment in patients with breast cancer", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4MWp96NkSFoC", "citedby": "4"}, {"bib": {"title": "Abstract S5-8: Parallel upregulation of Bcl2 and estrogen receptor (ER) expression in HER2+ breast cancer patients treated with neoadjuvant lapatinib.", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:nb7KW1ujOQ8C", "citedby": "4"}, {"bib": {"title": "P5-21-01: A Renewable Tissue Resource of Phenotypically Stable Human Breast Cancer Xenografts for Preclinical Studies.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:738O_yMBCRsC", "citedby": "4"}, {"bib": {"title": "Estrogen deprivation is crucial for the antitumor effect of fulvestrant and adding the HER inhibitor gefitinib delays acquired resistance in a xenograft model of ER-positive \u2026", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:1sJd4Hv_s6UC", "citedby": "4"}, {"bib": {"title": "Resistance to endocrine therapy in a xenograft model of HER-2 overexpressing breast cancer is accompanied by increased HER-2 but loss of IGF-1 receptor expression", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:P5F9QuxV20EC", "citedby": "4"}, {"bib": {"title": "Blockade of the estrogen receptor/growth factor cross-talk implicated in breast cancer tamoxifen resistance using a selective EGFR TK inhibitor.", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:CHSYGLWDkRkC", "citedby": "4"}, {"bib": {"title": "Prevention of breast cancer in MMTV-ErbB2 transgenic mice using the tyrosine kinase inhibitor, ZD1839 ('Iressa').", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:abG-DnoFyZgC", "citedby": "4"}, {"bib": {"title": "JNK and p38 MAP kinases potentially contribute to tamoxifen resistance of breast cancer via direct phosphorylation of both estrogen receptor and AIB1 coactivator", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:p2g8aNsByqUC", "citedby": "4"}, {"bib": {"title": "PAM50 HER2-enriched/ERBB2-high (HER2-E/ERBB2H) biomarker to predict response and survival following lapatinib (L) alone or in combination with trastuzumab (T) in HER2+ T \u2026", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:yFnVuubrUp4C", "citedby": "3"}, {"bib": {"title": "Gene Expression Signatures of PI3K Signaling Are Associated with Low ER Levels and the Luminal B Subtype in Breast Cancer Cell Lines and Human Tumors, and in Patients Predicts \u2026", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:UxriW0iASnsC", "citedby": "3"}, {"bib": {"title": "S20 Combined ER and HER-targeted therapy in breast cancer treatment", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:dshw04ExmUIC", "citedby": "3"}, {"bib": {"title": "Non-nuclear human estrogen receptor-alpha 36 (hER\u03b1-36) is expressed in ER, PR, and Her2 positive or negative breast cancer patients as well as cell lines, and physically \u2026", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:SP6oXDckpogC", "citedby": "3"}, {"bib": {"title": "Microscaled proteogenomic methods for precision oncology", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WHdLCjDvYFkC", "citedby": "2"}, {"bib": {"title": "HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: a systematic review and meta-analysis", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:q-HalDI95KYC", "citedby": "2"}, {"bib": {"title": "Molecular mechanisms of endocrine resistance", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:yqoGN6RLRZoC", "citedby": "2"}, {"bib": {"title": "Is ctDNA the Road Map to the Landscape of the Clonal Mutational Evolution in Drug Resistance? Lessons from the PALOMA-3 Study and Implications for Precision Medicine", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:LhH-TYMQEocC", "citedby": "2"}, {"bib": {"title": "Abstract P4-03-05: AP-1 as a potential mediator of resistance to the cyclin-dependent kinase (CDK) 4/6-inhibitor palbociclib in ER-positive endocrine-resistant breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:OTTXONDVkokC", "citedby": "2"}, {"bib": {"title": "Abstract S4-01: A novel BRD4 inhibitor enhances endocrine therapy efficacy and circumvents endocrine-resistance in estrogen receptor-positive breast cancer models", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:0N-VGjzr574C", "citedby": "2"}, {"bib": {"title": "Abstract P1-07-07: Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of estrogen-receptor positive breast cancers", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:JQOojiI6XY0C", "citedby": "2"}, {"bib": {"title": "Abstract P6-04-05: GPR110 overexpression increases tumorigenic potential of HER2+ breast cancer cells", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:fQNAKQ3IYiAC", "citedby": "2"}, {"bib": {"title": "Abstract PD1-2: PIK3CA mutations and/or low PTEN predict resistance to combined anti-HER2 therapy with lapatinib and trastuzumab and without chemotherapy in TBCRC006, a \u2026", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:SeFeTyx0c_EC", "citedby": "2"}, {"bib": {"title": "78O_PR The Role of Ap-1 in Endocrine-Resistant Breast Cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:tOudhMTPpwUC", "citedby": "2"}, {"bib": {"title": "\u03b16\u03b21 and \u03b16\u03b24 integrins and their critical role in promoting resistance to multiple treatment strategies for breast cancer", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:u9iWguZQMMsC", "citedby": "2"}, {"bib": {"title": "Tamoxifen's agonist effect on breast cancer growth is mediated by activation of EGFR/HER-2 with preservation of its antagonist effect on ER-dependent gene expression", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:geHnlv5EZngC", "citedby": "2"}, {"bib": {"title": "Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:wKETBy42zhYC", "citedby": "1"}, {"bib": {"title": "Abstract OT2-07-04: A phase 1b study of poziotinib in combination with T-DM1 in women with advanced or metastatic HER2-positive breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:MpfHP-DdYjUC", "citedby": "1"}, {"bib": {"title": "Abstract P6-09-02: Effects of palbociclib on thymidine kinase-1 (TK1) in hormone receptor positive (HR+) breast cancer cell lines", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:0CzhzZyukY4C", "citedby": "1"}, {"bib": {"title": "Abstract SY01-01: Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:KbBQZpvPDL4C", "citedby": "1"}, {"bib": {"title": "Abstract P2-09-12: Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy \u2026", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WJVC3Jt7v1AC", "citedby": "1"}, {"bib": {"title": "Independent validation of the HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage \u2026", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4vMrXwiscB8C", "citedby": "1"}, {"bib": {"title": "Hyperactive FOXA1 activates super-enhancer-engaged HIF2 alpha/EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:dBIO0h50nwkC", "citedby": "1"}, {"bib": {"title": "FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:LgRImbQfgY4C", "citedby": "1"}, {"bib": {"title": "Role of GPR110 on tumorigenesis and metastasis in HER2+ breast cancer in the context of anti-HER2 drug resistance", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:kRWSkSYxWN8C", "citedby": "1"}, {"bib": {"title": "Evaluation of tumor immune infiltrate as a determinant of response to neo-adjuvant lapatinib and trastuzumab (LT) in HER2-positive (+) breast cancer (BC).", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:kh2fBNsKQNwC", "citedby": "1"}, {"bib": {"title": "Abstract PD2-05: Evaluating the role of recurrent ESR1-CCDC170 in breast cancer endocrine resistance", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:eJXPG6dFmWUC", "citedby": "1"}, {"bib": {"title": "Mevalonate pathway mediates acquired anti-HER2 treatment resistance in HER2+ breast cancer", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:uWiczbcajpAC", "citedby": "1"}, {"bib": {"title": "Abstract P3-05-13: Overexpression of insulin receptor substrate 4 can mediate acquired resistance to lapatinib-containing regimens in HER2+ breast cancer cells", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:nrtMV_XWKgEC", "citedby": "1"}, {"bib": {"title": "Reduction in nanoparticle size dramatically improves plasmonic photo-thermal therapy efficacy in aggressive triple negative breast cancer", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:sSrBHYA8nusC", "citedby": "1"}, {"bib": {"title": "Abstract P2-09-08: Therapeutic potential of the dual HER1/2 inhibitor AZD8931 in circumventing endocrine resistance", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:8AbLer7MMksC", "citedby": "1"}, {"bib": {"title": "OVERCOMING ENDOCRINE THERAPY RESISTANCE DUE TO PI3K/AKT PATHWAY ACTIVATION BY COMBINATIONS OF mTOR, AKT, OR MEK INHIBITORS", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:BrmTIyaxlBUC", "citedby": "1"}, {"bib": {"title": "Abstract P4-06-02: Identification of novel G-protein coupled receptor targets in HER2-positive breast cancer.", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:L7CI7m0gUJcC", "citedby": "1"}, {"bib": {"title": "Abstract P6-04-25: Genomic Deregulation and Therapeutic Role of Nemo-like Kinase in Luminal B Breast Cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:5Ul4iDaHHb8C", "citedby": "1"}, {"bib": {"title": "Abstract PD09-08: The potential role of TLK2 as a therapeutic target in breast cancer.", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4fKUyHm3Qg0C", "citedby": "1"}, {"bib": {"title": "Calibrating the imaging and therapy performance of magneto-fluorescent gold nanoshells for breast cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:vRqMK49ujn8C", "citedby": "1"}, {"bib": {"title": "AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:6yz0xqPARnAC", "citedby": "1"}, {"bib": {"title": "P3-03-05: Identification of miRNAs and Their Associated Target Genes Involved in Endocrine Resistance in Breast Cancer.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:EkHepimYqZsC", "citedby": "1"}, {"bib": {"title": "P1-08-04: Obesity, Adjuvant Therapy, and Survival Outcomes in Early-Stage Breast Cancer.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:eflP2zaiRacC", "citedby": "1"}, {"bib": {"title": "Different Mechanisms for Acquired Resistance to Trastuzumab and Lapatinib in HER2 Positive Breast Cancers: Role of ER and HER2 Reactivation.", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:LPZeul_q3PIC", "citedby": "1"}, {"bib": {"title": "Crosstalk between estrogen receptor and growth factor receptor pathways as a mechanism of endocrine therapy resistance", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:D_sINldO8mEC", "citedby": "1"}, {"bib": {"title": "The estrogen receptor antagonist fluvestrant, but not the partial antagonist tamoxifen, is an effective endocrine treatment in a xenograft model of HER2 overexpressing breast \u2026", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:B3FOqHPlNUQC", "citedby": "1"}, {"bib": {"title": "Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:FiDNX6EVdGUC", "citedby": "0"}, {"bib": {"title": "Discovery, Structure\u2013Activity Relationship, and Biological Activity of Histone-Competitive Inhibitors of Histone Acetyltransferases P300/CBP", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:O0nohqN1r9EC", "citedby": "0"}, {"bib": {"title": "Author Correction: Temporal dynamic reorganization of 3D chromatin architecture in hormone-induced breast cancer and endocrine resistance", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:1DsIQWDZLl8C", "citedby": "0"}, {"bib": {"title": "ADGRF1 signaling pathways in Breast Cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:-95Q15plzcUC", "citedby": "0"}, {"bib": {"title": "Abstract PD2-02: Activation of the EGFR/RAS/p42, 44 MAPK axis as a convergent mechanism of resistance to CDK4/6 inhibitors in ER+ breast cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:OBSaB-F7qqsC", "citedby": "0"}, {"bib": {"title": "Abstract P3-06-07: ADGRF1 overexpression inhibits tumor growth in vivo by inducing cell cycle arrest in HER2+ breast cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:MAUkC_7iAq8C", "citedby": "0"}, {"bib": {"title": "Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Dem6FJhTUoYC", "citedby": "0"}, {"bib": {"title": "Abstract PD7-01: Identification of a high FOXA1-induced pro-metastatic enhancer signature in endocrine-resistant and metastatic breast cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:jE2MZjpN3IcC", "citedby": "0"}, {"bib": {"title": "Abstract P6-04-02: Integrative cistromic/transcriptomic profiling identifies a high FOXA1/ER-activated pro-metastatic secretome in endocrine-resistant breast cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:-7ulzOJl1JYC", "citedby": "0"}, {"bib": {"title": "Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WC23djZS0W4C", "citedby": "0"}, {"bib": {"title": "Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:SjuI4pbJlxcC", "citedby": "0"}, {"bib": {"title": "In vivo longitudinal imaging of RNA interference\u2010induced endocrine therapy resistance in breast cancer", "year": "2020"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:j7_hQOaDUrUC", "citedby": "0"}, {"bib": {"title": "119P ERBB2 mRNA as a predictor in HER2-positive (HER2+)/hormone receptor-positive (HR+) metastatic breast cancer (BC) treated with HER2 blockade in combination with endocrine \u2026", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:1taIhTC69MYC", "citedby": "0"}, {"bib": {"title": "Single-cell transcriptomic characterization of luminal breast cancer cell lines with acquired resistance to the CDK4/6 inhibitor palbociclib", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:jgBuDB5drN8C", "citedby": "0"}, {"bib": {"title": "Targeting the mevalonate pathway in HER2+ breast cancer to overcome resistance and enhance anti-HER2 therapy efficacy", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ubry08Y2EpUC", "citedby": "0"}, {"bib": {"title": "The therapeutic superiority of neratinib in combination with trastuzumab compared to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:1lhNe0rCu4AC", "citedby": "0"}, {"bib": {"title": "The role of GPR110 in tumorigenicity, tumor cell dissemination, and cell cycle regulation in HER2+ breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ALROH1vI_8AC", "citedby": "0"}, {"bib": {"title": "Therapeutic role of ESR1-CCDC170 gene fusion in breast cancer endocrine resistance", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:lgwcVrK6X84C", "citedby": "0"}, {"bib": {"title": "OMICS analysis of breast cancer PDX tumors to determine CTC-cluster-specific signature in predicting breast cancer metastasis", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:48xauSegjOkC", "citedby": "0"}, {"bib": {"title": "Novel neoplastic RAD51AP1-DYRK4 fusion transcript in aggressive luminal breast cancers", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:CaZNVDsoPx4C", "citedby": "0"}, {"bib": {"title": "Abstract P6-20-10: Role of GPR110 in breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:DBa1UEJaJKAC", "citedby": "0"}, {"bib": {"title": "Abstract P2-08-06: Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:uDGL6kOW6j0C", "citedby": "0"}, {"bib": {"title": "Abstract P6-17-12: Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:PVgj2kMGcgYC", "citedby": "0"}, {"bib": {"title": "Abstract P4-15-05: Biomarkers of response to neoadjuvant endocrine therapy with anastrozole (Ana) alone or in combination with fulvestrant (Ful) in ER-positive (ER+) HER2 \u2026", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:NyGDZy8z5eUC", "citedby": "0"}, {"bib": {"title": "Role of GPR110 in breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:HhcuHIWmDEUC", "citedby": "0"}, {"bib": {"title": "Biomarkers of response to neoadjuvant endocrine therapy with anastrozole (Ana) alone or in combination with fulvestrant (Ful) in ER-positive (ER+) HER2-negative (HER2-) breast \u2026", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:nRpfm8aw39MC", "citedby": "0"}, {"bib": {"title": "Neratinib in combination with trastuzumab is superior to each alone and to pertuzumab plus trastuzumab in HER2-positive in vivo breast cancer models", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:PaBasH6fAo0C", "citedby": "0"}, {"bib": {"title": "Standardized nCounter-based determination of estrogen receptor (ER), progesterone receptor (PR) and HER2 receptor status in breast cancer", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:7Hz3ACDFbsoC", "citedby": "0"}, {"bib": {"title": "Coordinate Enhancer Reprogramming by GATA3 and AP1 Promotes Phenotypic Plasticity to Achieve Breast Cancer Endocrine Resistance", "year": "2019"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:IaI1MmNe2tcC", "citedby": "0"}, {"bib": {"title": "Endocrine resistance in metastatic breast cancer: Mechanisms and new therapeutic strategies", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:w0F2JDEymm0C", "citedby": "0"}, {"bib": {"title": "Npy1r as a prognostic marker and a novel drug target in estrogen receptor-positive breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:fFSKOagxvKUC", "citedby": "0"}, {"bib": {"title": "Abstract P4-03-04: Targeting the mevalonate pathway in HER2-positive breast cancer to overcome resistance to anti-HER2 therapy", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:IUKN3-7HHlwC", "citedby": "0"}, {"bib": {"title": "Abstract P3-06-03: Dual p38/NLK kinase inhibitor as potential novel therapeutic agent for tamoxifen-resistant luminal breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:mlAyqtXpCwEC", "citedby": "0"}, {"bib": {"title": "Abstract P4-04-03: Hyperactive FOXA1 activates super-enhancer-engaged HIF2\u03b1/EPAS1 to promote endocrine-resistant metastatic ER-positive breast cancer", "year": "2018"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:IRz6iEL74y4C", "citedby": "0"}, {"bib": {"title": "Evaluation of the dual p38/NLK kinase inhibitor as potential new therapeutic agent for tamoxifen-resistant breast cancer", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:HtEfBTGE9r8C", "citedby": "0"}, {"bib": {"title": "Evaluating the role of recurrent ESR1-CCDC170 fusion in breast cancer endocrine resistance", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:NXb4pA-qfm4C", "citedby": "0"}, {"bib": {"title": "46PMetabolomic analysis as a tool to identify breast cancer (BC) cell lines resistant to palbociclib (PD)", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:YohjEiUPhakC", "citedby": "0"}, {"bib": {"title": "Abstract ES7-3: ES7-3 Mechanisms of resistance to Her2 positive disease", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hCrLmN-GePgC", "citedby": "0"}, {"bib": {"title": "Abstract P3-04-07: The new oral SERD AZD9496 is efficacious in antagonizing ER and circumventing resistance to endocrine therapy", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ClCfbGk0d_YC", "citedby": "0"}, {"bib": {"title": "Abstract PD2-04: FOXA1 induces a pro-metastatic secretome through ER-dependent and independent transcriptional reprogramming in endocrine-resistant breast cancer", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:FPJr55Dyh1AC", "citedby": "0"}, {"bib": {"title": "Abstract P6-02-07: Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to \u2026", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Ug5p-4gJ2f0C", "citedby": "0"}, {"bib": {"title": "Metabolomic analysis by nuclear magnetic resonance spectroscopy discriminates hormone receptor positive/HER2 negative breast cancer cell lines resistant to palbociclib", "year": "2017"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:AHdEip9mkN0C", "citedby": "0"}, {"bib": {"title": "CTCs and CTC clusters in breast cancer patient-\u2010derived xenograft models", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ILKRHgRFtOwC", "citedby": "0"}, {"bib": {"title": "Clonal evolution of the HER2 L755S mutation leads to acquired HER-targeted therapy resistance that can be reversed by the irreversible HER1/2 inhibitor afatinib", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:tYavs44e6CUC", "citedby": "0"}, {"bib": {"title": "Collection, high-resolution imaging, and single cell isolation of circulating tumor cells from patient derived xenograft models using the AccuCyte (R)-CyteFinder (R) system", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:F1b5ZUV5XREC", "citedby": "0"}, {"bib": {"title": "Abstract P2-02-07: Collection, high-resolution imaging, and single cell isolation of circulating tumor cells from patient derived xenograft models using the AccuCyte \u2026", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:mvPsJ3kp5DgC", "citedby": "0"}, {"bib": {"title": "Mechanisms of action of selective estrogen receptor modulators and down regulators", "year": "2016"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:QYdC8u9Cj1oC", "citedby": "0"}, {"bib": {"title": "Abstract A62: PARP-1 regulates NF-\u03baB-mediated IL-8 expression in HER2 positive breast cancer", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:vbGhcppDl1QC", "citedby": "0"}, {"bib": {"title": "Targeting GPR110 in HER2-Overexpressing Breast Cancers", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:edDO8Oi4QzsC", "citedby": "0"}, {"bib": {"title": "PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER plus) breast cancer models", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:vDZJ-YLwNdEC", "citedby": "0"}, {"bib": {"title": "Novel G protein-coupled receptor targets in HER2+ breast cancer", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Z5m8FVwuT1cC", "citedby": "0"}, {"bib": {"title": "Genomic deregulation and therapeutic role of the cell-cycle kinase TLK2 in more aggressive breast cancers", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:evX43VCCuoAC", "citedby": "0"}, {"bib": {"title": "Combined inhibition of non-canonical HER2 signaling as a strategy to overcome resistance to HER2-targeted therapies", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:LjlpjdlvIbIC", "citedby": "0"}, {"bib": {"title": "Clonal evolution of the HER2 L755S mutation as a mechanism of acquired HER-targeted therapy resistance", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_B80troHkn4C", "citedby": "0"}, {"bib": {"title": "Abstract LB-166: PARP inhibition effects on endocrine therapy and resistance in estrogen receptor positive (ER+) breast cancer models", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:eMMeJKvmdy0C", "citedby": "0"}, {"bib": {"title": "Crosstalk between PARP-1 and NF-\u03baB signaling pathways as a potential determinant of PARPi sensitivity in trastuzumab resistant HER2+ breast cancer cell lines.", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:XoXfffV-tXoC", "citedby": "0"}, {"bib": {"title": "Abstract P4-01-06: Circulating and disseminated tumor cells from breast cancer patient-derived xenograft-bearing mice as a novel model to study metastasis", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Bg7qf7VwUHIC", "citedby": "0"}, {"bib": {"title": "Abstract P5-05-01: Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:epqYDVWIO7EC", "citedby": "0"}, {"bib": {"title": "Abstract P6-11-01: A broad spectrum therapeutic strategy for TNBC revealed by a new pathway that coordinates oncogenic RTKs", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:35r97b3x0nAC", "citedby": "0"}, {"bib": {"title": "Abstract P3-05-03: Reversal of endocrine therapy resistance with inhibitors of AKT, mTOR, or MEK as single agents or in combination", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:tkaPQYYpVKoC", "citedby": "0"}, {"bib": {"title": "Abstract PD6-2: FoxA1 gene amplification in ER+ breast cancer mediates endocrine resistance by increasing IL-8", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:olpn-zPbct0C", "citedby": "0"}, {"bib": {"title": "Abstract P5-05-03: Clonal evolution of the HER2 L755S mutation leads to acquired HER-targeted therapy resistance that can be reversed by the irreversible HER1/2 inhibitor afatinib", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:1qzjygNMrQYC", "citedby": "0"}, {"bib": {"title": "PG 7.03 The changing role of ER in endocrine resistance", "year": "2015"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:uLbwQdceFCQC", "citedby": "0"}, {"bib": {"title": "Sub-100 nm gold nanomatryoshkas improve photo-thermal therapy efficacy in large and highly aggressive triple negative breast tumors", "year": "2014"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:HE397vMXCloC", "citedby": "0"}, {"bib": {"title": "Development of a novel selective estrogen receptor down-regulator which shows efficacy in pre-clinical models of endocrine resistance", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Ak0FvsSvgGUC", "citedby": "0"}, {"bib": {"title": "Abstract P3-04-04: Amplification and overexpression of TLK2 promote genomic instability in invasive breast cancer", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:uc_IGeMz5qoC", "citedby": "0"}, {"bib": {"title": "Abstract P5-09-20: Development of a novel selective estrogen receptor down-regulator which shows efficacy in pre-clinical models of endocrine resistance", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:AXPGKjj_ei8C", "citedby": "0"}, {"bib": {"title": "PMCID: PMC3668728.", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_Re3VWB3Y0AC", "citedby": "0"}, {"bib": {"title": "Acquired therapeutic resistance is mediated by deregulation of multiple pathways.", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ipzZ9siozwsC", "citedby": "0"}, {"bib": {"title": "Contents of Forthcoming Issues\u00b7 Themenvorschau", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:LO7wyVUgiFcC", "citedby": "0"}, {"bib": {"title": "Innovationen\u00b7 Innovations", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:FAceZFleit8C", "citedby": "0"}, {"bib": {"title": "Imprint", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:_FM0Bhl9EiAC", "citedby": "0"}, {"bib": {"title": "Vol. 8, Issue 4, August 2013/Band 8, Heft 4, August 2013", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:GtLg2Ama23sC", "citedby": "0"}, {"bib": {"title": "PharmaNews/PharmaTicker", "year": "2013"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:9pM33mqn1YgC", "citedby": "0"}, {"bib": {"title": "Abstract P6-10-03: The PKC inhibitor PKC412 antagonizes breast cancer cell growth and enhances tamoxifen sensitivity", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:uJ-U7cs_P_0C", "citedby": "0"}, {"bib": {"title": "Abstract P6-05-12: Lack of Frequent Estrogen Receptor Mutation in Primary Breast Tumors", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:N5tVd3kTz84C", "citedby": "0"}, {"bib": {"title": "Abstract PD01-01: Overcoming endocrine therapy resistance related to PTEN loss by strategic combinations with mTOR, AKT, or MEK inhibitors", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:VL0QpB8kHFEC", "citedby": "0"}, {"bib": {"title": "Die and let live: harnessing BikDD to combat breast cancer stem cells", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:eq2jaN3J8jMC", "citedby": "0"}, {"bib": {"title": "Molecular biology (pre-clinical)", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:EYYDruWGBe4C", "citedby": "0"}, {"bib": {"title": "Circulating tumor cells as a novel model to test efficacy of individualized therapy in breast cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:tH6gc1N1XXoC", "citedby": "0"}, {"bib": {"title": "Abrogating tamoxifen resistance with the ribonucleoside analog, 8-amino adenosine", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:zLWjf1WUPmwC", "citedby": "0"}, {"bib": {"title": "Abstract LB-305: Circulating tumor cells as a novel model to test efficacy of individualized therapy in breast cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:z_wVstp3MssC", "citedby": "0"}, {"bib": {"title": "The role of miRNAs in tamoxifen resistance in breast cancer: O25", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:-_dYPAW6P2MC", "citedby": "0"}, {"bib": {"title": "Mirnas: Small molecules, big players in tamoxifen resistance in breast cancer", "year": "2012"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:XiVPGOgt02cC", "citedby": "0"}, {"bib": {"title": "P4-07-03: Identification of Triple-Negative Primary Breast Cancer Xenograft Models with High Numbers of Circulating and Disseminated Tumor Cells.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ML0RJ9NH7IQC", "citedby": "0"}, {"bib": {"title": "P4-01-03: Establishment and Characterization of an Endocrine Resistance Model In Vitro and In Vivo by Inducible PTEN Knockdown.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:tzM49s52ZIMC", "citedby": "0"}, {"bib": {"title": "P4-01-02: Endocrine Resistance: Mechanism, Tumorigenic Capacities, and New Therapeutic Strategies.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Fu2w8maKXqMC", "citedby": "0"}, {"bib": {"title": "P4-01-18: AP-1 Blockade Potentiates the Anti-Tumor Effect of Endocrine Treatment and Reverts the Resistant Phenotype in Hormone Receptor-Positive Breast Cancer.", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:tS2w5q8j5-wC", "citedby": "0"}, {"bib": {"title": "MIRNA signatures as predictors of resistance to endocrine and HER2 targeted therapy", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WA5NYHcadZ8C", "citedby": "0"}, {"bib": {"title": "Crosstalk between ER and PI3K signaling pathways in human luminal type breast cancer and its therapeutic implications", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ZfRJV9d4-WMC", "citedby": "0"}, {"bib": {"title": "S07 Overcoming resistance to endocrine therapies: Multiple interventions to reach the goal", "year": "2011"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:UHK10RUVsp4C", "citedby": "0"}, {"bib": {"title": "Plasticity of the ER and HER2 Signaling Networks Results in Compensatory Escape Pathways Contributing to Treatment Resistance", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:2tRrZ1ZAMYUC", "citedby": "0"}, {"bib": {"title": "Abstract P4-02-20: Plasticity of the ER and HER2 Signaling Networks Results in Compensatory Escape Pathways Contributing to Treatment Resistance", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:5awf1xo2G04C", "citedby": "0"}, {"bib": {"title": "Abstract P2-06-09: Mucin4 Is Associated with the Loss of Estrogen-Receptor-\u03b1 in Breast Cancer", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:JoZmwDi-zQgC", "citedby": "0"}, {"bib": {"title": "Abstract S6-10: Identification of a Novel Tumor Suppressor Network Reveals a Role for Proto-Oncogenic Receptor Tyrosine Kinases in Triple-Negative Breast Cancer", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:q3oQSFYPqjQC", "citedby": "0"}, {"bib": {"title": "UNDERSTANDING AND OVERCOMING RESISTANCE TO HORMONAL THERAPY", "year": "2010"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:bnK-pcrLprsC", "citedby": "0"}, {"bib": {"title": "Vandetanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (HER1), Potentiates Anti-Tumor Effects of Combined \u2026", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:t6usbXjVLHcC", "citedby": "0"}, {"bib": {"title": "Efficient generation of primary xenografts using normal and malignant human mammary epithelium in SCID/Beige mice without humanizing fibroblasts", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:XD-gHx7UXLsC", "citedby": "0"}, {"bib": {"title": "Abstract# 754: The role of JNK/AP1 and p38 stress-activated protein kinase pathways in the development of endocrine resistance in breast cancer", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:WqliGbK-hY8C", "citedby": "0"}, {"bib": {"title": "Abstract# 3223: Efficient generation of primary xenografts using normal and malignant human mammary epithelium in SCID/Beige mice without humanizing fibroblasts", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:V3AGJWp-ZtQC", "citedby": "0"}, {"bib": {"title": "Combination antiHER therapeutics\u2014efficacy of alternative dosing regimens in ER+/HER2+ breast cancer xenografts.", "year": "2009"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:VLnqNzywnoUC", "citedby": "0"}, {"bib": {"title": "PMCID: PMC3522262.", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:TIZ-Mc8IlK0C", "citedby": "0"}, {"bib": {"title": "Reverse phase protein array analysis of an ER-positive/HER2-positive breast cancer xenograft model reveals distinct resistance mechanisms to HER2 targeted therapy", "year": "2008"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:wbdj-CoPYUoC", "citedby": "0"}, {"bib": {"title": "Development of resistance to targeted therapy strategies transforms the clinically-defined molecular profile subtype of breast tumors", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hMsQuOkrut0C", "citedby": "0"}, {"bib": {"title": "Dual-labeled trastuzumab-based imaging agent for the detection of human epidermal growth factor receptor-2 (HER2) overexpression in breast cancer", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:AvfA0Oy_GE0C", "citedby": "0"}, {"bib": {"title": "Targeting the HER network in breast cancer: therapeutic successes and failures", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:j8SEvjWlNXcC", "citedby": "0"}, {"bib": {"title": "\u03b16\u03b21 and \u03b16\u03b24 integrins and their critical role in promoting resistance to multiple treatment strategies for breast cancer", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:tKAzc9rXhukC", "citedby": "0"}, {"bib": {"title": "Reverse phase protein array analysis of an ER-positive/HER2-positive breast cancer xenograft model reveals distinct resistance mechanisms to HER2 targeted therapy", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:dQ2og3OwTAUC", "citedby": "0"}, {"bib": {"title": "Breast tumor xenografts of luminal subtype switch to the ERBB2+ molecular subtype in response to endocrine therapy: Gene expression profiling may not predict pathways of \u2026", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:W5xh706n7nkC", "citedby": "0"}, {"bib": {"title": "BASIC SCIENCE INVESTIGATIONS-Dual-Labeled Trastuzumab-Based Imaging Agent for the Detection of Human Epidermal Growth Factor Receptor 2 Overexpression in Breast Cancer", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:BJbdYPG6LGMC", "citedby": "0"}, {"bib": {"title": "Reversal of the Estrogen Receptor: Negative Phenotype in Breast Cancer and Restoration of Antiestrogen Response. Commentary", "year": "2007"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:J-pR_7NvFogC", "citedby": "0"}, {"bib": {"title": "Gene expression and protein profiling of estrogen receptor positive vs. negative HER2-overexpressing xenograft tumors", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:PELIpwtuRlgC", "citedby": "0"}, {"bib": {"title": "Can biomarkers direct the optimal use of aromatase inhibitors versus selective estrogen receptor modulators?", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ZuybSZzF8UAC", "citedby": "0"}, {"bib": {"title": "Correspondence-In Reply-Progesterone Receptor in Estrogen Receptor-Positive Breast Cancer: The Association Between HER-2 and Lymph Node Involvement Is Age Related", "year": "2006"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:3htObqc8RwsC", "citedby": "0"}, {"bib": {"title": "An important role for AIB1 phosphorylation in mediating growth factor signaling dependent estrogen agonist activity of tamoxifen in breast cancer cells", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:yB1At4FlUx8C", "citedby": "0"}, {"bib": {"title": "An important role for AIB1 phosphorylation in the estrogen agonist activity of tamoxifen", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:PR6Y55bgFSsC", "citedby": "0"}, {"bib": {"title": "Thematic review series-Endocrinology and hormone therapy in breast cancer-New insight into estrogen receptor-a function and its implication for endocrine therapy resistance in \u2026", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:4X0JR2_MtJMC", "citedby": "0"}, {"bib": {"title": "Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first-and second-line chemotherapy in advanced \u2026", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:DJbcl8HfkQkC", "citedby": "0"}, {"bib": {"title": "Original Reports-PREDICTIVE BIOMARKERS/TRANSLATIONAL RESEARCH-Molecular Changes in Tamoxifen-Resistant Breast Cancer: Relationship between Estrogen Receptor, HER-2, and p38 \u2026", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:t7zJ5fGR-2UC", "citedby": "0"}, {"bib": {"title": "Chapter 14: Crosstalk Between Estrogen-Receptor and Growth-Factor-Receptor Pathways as a Mechanism of Endocrine Therapy Resistance", "year": "2005"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:fEOibwPWpKIC", "citedby": "0"}, {"bib": {"title": "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:OR75R8vi5nAC", "citedby": "0"}, {"bib": {"title": "Breast cancer: Prognosis, Treatment and Prevention", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:S16KYo8Pm5AC", "citedby": "0"}, {"bib": {"title": "The growth hormone antagonist pegvisomant (somavert\u00ae) blocks normal mammmary gland development and causes regression of MCF-7 human breast tumor xenografts", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:7T2F9Uy0os0C", "citedby": "0"}, {"bib": {"title": "Gene expression profiles of endocrine resistant HER2-overexpressing breast xenograsfts", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:hkOj_22Ku90C", "citedby": "0"}, {"bib": {"title": "658 An essential role for AIB1 phosphorylation in tamoxifen resistance", "year": "2004"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:5ugPr518TE4C", "citedby": "0"}, {"bib": {"title": "Increased agonist activity of tamoxifen is associated with growth factor modulation of estrogen receptor coregulatory proteins and is reversed by receptor tyrosine kinase \u2026", "year": "2003"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ye4kPcJQO24C", "citedby": "0"}, {"bib": {"title": "Breast Cancer: Prognosis, Treatment and Prevention", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:e_rmSamDkqQC", "citedby": "0"}, {"bib": {"title": "Faslodex, a new pure antagonist for endocrine therapy of breast cancer", "year": "2002"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:kzcrU_BdoSEC", "citedby": "0"}, {"bib": {"title": "The FKHR family-estrogen receptor co-repressors and potential tumor suppressors.", "year": "2001"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:vDijr-p_gm4C", "citedby": "0"}, {"bib": {"title": "Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer-Estrogen Receptor: Current Understanding of \u2026", "year": "2001"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:SdhP9T11ey4C", "citedby": "0"}, {"bib": {"title": "Inhibition of AP-1 Suppresses the In Vitro and In Vivo Growth of MCF-7 Breast Cancer.", "year": "2000"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:VOx2b1Wkg3QC", "citedby": "0"}, {"bib": {"title": "Antitumor activity of tamoxifen loaded solid lipid nanoparticles on induced mammary tumor gland in Sprague-Dawley rats.", "year": "2000"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:ODE9OILHJdcC", "citedby": "0"}, {"bib": {"title": "Tamoxifen-stimulated breast tumor growth correlates with oxidative stress and increased JNK activity", "year": "1999"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:9vf0nzSNQJEC", "citedby": "0"}, {"bib": {"title": "Tamoxifen-stimulated breast tumor growth is associated with cellular oxidative stress and increased JNK activity", "year": "1998"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:NJ774b8OgUMC", "citedby": "0"}, {"bib": {"title": "Cell type and development specifications of murine retrotransposon expression", "year": "1989"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:2KloaMYe4IUC", "citedby": "0"}, {"bib": {"title": "PMC2948755."}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:Br1UauaknNIC", "citedby": "0"}, {"bib": {"title": "Advances and Future Directions in Endocrine Manipulation of Breast Cancer: Conference Summary Statement"}, "source": "citations", "id_citations": "1EPjsEMAAAAJ:6ZxmRoH8BuwC", "citedby": "0"}]}